EMEA-002224-PIP01-17
Key facts
| Active substance |
Synthetic double-stranded small interfering RNA (siRNA) oligonucleotide specific to the mRNA of the caspase 2 gene
|
| Therapeutic area |
Ophthalmology
|
| Decision number |
P/0394/2017
|
| PIP number |
EMEA-002224-PIP01-17
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of optic ischaemic neuropathy
|
| Route(s) of administration |
Intravitreal use
|
| Contact for public enquiries |
Quark Pharmaceuticals, Inc.
Tel. +1 5103645121
E-mail: DCafaro@quarkpharma.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|